Expression proteomics includes the study of the dysregulated proteins as a function of stimulation or patient condition. The patient condition depends on the disease or specific drugs related to any disease. The market for expression proteomics is segmented into four major categories, on the basis of applications, by expression system, by products and by the End users. By expression system, market of expression proteomics consists of four segments including:
Among the expression system segments, the major market share is commanded by prokaryotic segment. The use of Escherichia Coli (E.Coli) is mostly preferred as a host cell due to its easy availability and cheap protein expression and production. Mammalian segment is also showing increased growth as demand for therapeutic proteins has increased leading to need for proteins with post-translational modification and increasing use of mammalian expression systems.
The market for expression proteomics on the basis of the product is differentiated into four major segments which include:
- Competent Cells
- Expression vectors
In the product segment for expression proteomics market, reagents is the major revenue generating product driven by the demand of immunoassays, microarray reagents and spectroscopy reagents. These reagents are easy to use and are less expensive comparatively and therefore, used in large number for transfection and maintenance of cell lines. Instruments are further divided into six major categories according to the techniques involved in expression proteomics namely microarrays, mass spectrometers, NMR spectrometers, chromatography, electrophoresis, surface plasmon resonance and X-ray crystallography. Among these protein microarrays are dominating the market followed by spectroscopy technique.
On the basis of application of expression proteomics, the market is divided into three segments including:
- Industrial proteins
- Research applications
- Therapeutic proteins
Among these segments, therapeutic proteins are dominating the market for expression proteomics due to its versatile advantage over other small molecule drugs to alleviate diseases. On the basis of end users, the market is majorly classified into three parts namely pharmaceutical, biotechnology and research organizations.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2440
The market for expression proteomics is growing at faster pace majorly driven by the globally increasing intensity in research in the pharmaceutical and biological sector. Additionally, the factors such as increased demand for personalized medicine, technological advancement and increasing use of proteomic outcomes in diagnosis and drug discovery also propels the market growth. However, reduction in funding towards sequestration cuts in U.S., high cost of expression proteomics tools, difficulty in gaining regulatory approvals and dearth of qualified researchers are some of the factors which are restraining the growth of this market to some extent.
North America currently leads the global market for expression proteomics followed by Europe. The major factors driving the expression proteomics market in these regions are the technological advancements and rising demand for the expression proteomics in personalized medicines. The expression proteomics market in Asia-Pacific is also showing rapid growth due to increasing government and private funding towards research and development in countries such as Japan, India, Australia and China. The major key players in the expression proteomics market include ActivX Biosciences, Inc, Agilent Technologies, Inc., Life Technologies Corporation, New England Biolabs, Inc., QIAGEN, Takara Bio, Inc., Bio-Rad Laboratories, Merck Millipore, Hybrigenics SA , Tyrian Diagnostics, Ltd, Luminex Corporation, Promega Corporation, Danaher Corporation , Caprion Proteomics, Inc Sigma-Aldrich Corporation and Thermo Fischer Scientific, Inc.